Key facts
- This page summarizes Fred Aslan's Form 3 filing for Artiva Biotherapeutics, Inc. (ARTV).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 18 Jul 2024, 20:00.
Fred Aslan - 18 Jul 2024 Form 3 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ARTV
- Reported as of
- 18 Jul 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 18 Jul 2024, 20:00:09 UTC
- Next SEC filing
- 07 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Bush, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Fred Aslan filed Form 3 for Artiva Biotherapeutics, Inc. (ARTV) on 18 Jul 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARTV
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 257,319
- Exercise price
- $5.01
- Footnotes
- F1
ARTV
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51,463
- Exercise price
- $5.01
- Footnotes
- F2
ARTV
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,577
- Exercise price
- $5.01
- Footnotes
- F3
ARTV
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,450
- Exercise price
- $5.18
- Footnotes
- F4
ARTV
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 113,999
- Exercise price
- $13.47
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
25% of the shares vested on January 1, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
Footnote F2
25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
Footnote F3
25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
Footnote F4
Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.
Footnote F5
25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.